Orthotopic and Bioluminescent Models

Improve the predictive value of preclinical models with organ-specific TME and track disease progression in real time


Predictive Preclinical Benefits of Orthotopic Models

Orthotopic tumor models provide a clinically relevant, organ-specific tumor microenvironment (TME) to improve preclinical predictivity over subcutaneous alternatives. Generated by seeding tumor cells at the organ-specific site of the original tumor, orthotopic models mimic the primary lesion and establish better tumor, stroma, and immune component interactions than subcutaneous implantation.

This allows more human-disease relevant tumor development and progression, including spontaneous metastasis, recapitulating late-stage tumors. Orthotopic models therefore provide the ideal setting to:

  • investigate disease mechanisms
  • target the metastatic niche with new therapeutics
  • generate more patient-relevant response or resistance to anticancer agents.

Optical Imaging to Track Disease Progression and Metastasis

Orthotopic metastatic models are most powerful when the disease is tracked in vivo in real time by optical imaging of luciferase-labeled tumor cells.

comparing CCl4 NASH induction in conventional and MS-NASH dysmetabolic models

Figure 1: Luciferase-labeled model establishment by lentiviral transduction

Our collection of luciferase-labeled validated in vivo models allow you to non-invasively monitor the longitudinal growth of a tumor and to track tumor response to your treatment in real time, saving time and resources.

Advantages of Imaging Orthotopic Models  

Validated Bioluminescent Models